NCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
Novartis
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Sotio Biotech Inc.